Transmissible encephalopathies in humans and other mammals (for review, see (
Harris & True, 2006;
Prusiner, 1998;
Weissmann, 2004) and cytoplasmically heritable traits in yeast and other fungi (for review, see
Inge-Vechtomov et al., 2007;
Wickner et al., 2007a;
Wickner et al., 2007b) are controlled by abnormal, self-perpetuating protein isoforms termed prions. Most prions are cross-β polymers (amyloids) thought to propagate by immobilizing normal monomeric protein of the same amino acid (aa) sequence and converting it into a prion form (
Lansbury & Caughey, 1995).
The ability of a pre-existing amyloid to convert normal protein into a prion requires a high level of identity between interacting protein sequences. Therefore, transmission of a mammalian prion disease to another mammalian species is usually inefficient due to the so-called species barrier. However, cross-species conversion may overcome the barrier, for example, as in the case of “mad cow” disease (for reviews, see
Collinge & Clarke, 2007;
Prusiner, 1998). Transmissibility of this disease to humans forced the large-scale extermination of potentially infected cows in Europe in the 1990s and massive beef recalls in the USA in the 2000s. Despite the importance of the species barrier for both practical (prediction of cross-species infectivity) and fundamental (deciphering the molecular basis of amyloid specificity) purposes, its mechanism is still poorly understood. For mammalian prion protein (PrP), a correlation between the results of
in vitro or
in situ cross-seeding assays and
in vivo transmission barriers remains questionable (
Chernoff, 2004b;
Makarava et al., 2007).
To complicate matters further, a protein of one and the same sequence can form different prion variants or “strains,” distinguishable from each other by both phenotypic characteristics (e. g. incubation periods in mammals, or mitotic stability and level of impairment of the protein function in yeast) and biochemical patterns (e. g. protease digestion profiles, average aggregate size, and proportion of aggregated versus monomeric protein). Furthermore, mammalian prion variants may differ in host specificity (
Collinge & Clarke, 2007), and variant-specific patterns are usually maintained during cross-species conversion (
Bruce et al., 1994), with some exceptions in cases of prion “adaptation” for more efficient propagation in a new host. This is hypothetically explained by either conformational or kinetic selection (
Collinge & Clarke, 2007).
Prion potential of yeast prion proteins is controlled by terminally located and rapidly evolving prion domains (PrDs), that range from 65 to several hundred aa in size and are usually dispensable for the normal cellular function of a respective protein (for review, see (
Inge-Vechtomov et al., 2007;
Wickner et al., 2007a;
Wickner et al., 2007b). Strict prion species barriers were detected between the
Saccharomyces cerevisiae prion protein Sup35 and its distantly related orthologs from the yeast
Pichia methanolica or
Candida albicans, that possessed PrDs with only 30-40% of aa identity to
S. cerevisiae (
Chernoff et al., 2000;
Kushnirov et al., 2000;
Santoso et al., 2000). These barriers were controlled by the N-terminal, QN-rich regions and coincided with an inability of the divergent PrDs to coaggregate. Occasional cross-species transmission generated multiple prion variants (
Vishveshwara & Liebman, 2009), in contrast to intraspecies transmission that faithfully reproduces patterns of one and the same prion variant. This suggests that the species barrier was crossed due to a non-specific nucleation of the host protein by the aggregated heterologous protein, a phenomenon that is also observed with low frequency for non-homologous prion proteins with similar aa compositions (
Derkatch et al., 2001;
Osherovich & Weissman, 2001). Relevance of these data to the mammalian species barriers remains unclear due to much lower levels of sequence divergence among mammalian PrPs.
The prion species barrier was also detected for some combinations of more closely related orthologs of the yeast prion protein Ure2, originating from different Saccharomyces species (
Baudin-Baillieu et al., 2003;
Edskes et al., 2009;
Edskes & Wickner, 2002). As in mammals, Ure2 prion variants differed by host specificity; however, variant-specific patterns were faithfully reproduced during cross-species transmission (
Edskes et al., 2009).
To study the prion species barrier, we have previously developed a yeast-based experimental model that employs orthologs of the Sup35 prion protein from closely related Saccharomyces species (
Chen et al., 2007). The range of divergence among these proteins overlaps the range of divergence among mammalian PrP orthologs. Even though closely related Saccharomyces Sup35 proteins were capable of co-aggregating, transmission of the prion state from one protein to another was impaired, resulting in a species barrier. Our new studies demonstrate that differences between yeast prion variants influence heterologous coaggregation, cross-species transmission, and the ability to faithfully reproduce variant-specific patterns via a heterologous protein. Our data also identify potential aa stretches within the Sup35 PrD that are involved in the control of species specificity.